DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Pacritinib is an investigational drug.
There have been 22 clinical trials for Pacritinib. The most recent clinical trial was a Phase 1 trial, which was initiated on December 1st 2013.
The most common disease conditions in clinical trials are Primary Myelofibrosis, Leukemia, and Thrombocythemia, Essential. The leading clinical trial sponsors are CTI BioPharma, Covance, and Washington University School of Medicine.
There are eleven US patents protecting this investigational drug and one hundred and seven international patents.
Recent Clinical Trials for Pacritinib
|Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders||University of Michigan Cancer Center||Phase 1|
|Dose-Finding Study of Pacritinib in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib||Covance||Phase 2|
|Dose-Finding Study of Pacritinib in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib||CTI BioPharma||Phase 2|
Top disease conditions for Pacritinib
Top clinical trial sponsors for Pacritinib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Pacritinib||See Pricing||Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections||EMORY UNIVERSITY (Atlanta, GA)||See Pricing|
|Pacritinib||See Pricing||Biomarkers and combination therapies using oncolytic virus and immunomodulation||DNATRIX, INC. (Houston, TX) BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (Austin, TX)||See Pricing|
|Pacritinib||See Pricing||Oxygen linked pyrimidine derivatives||S*BIO Pte Ltd. (Singapore, SG)||See Pricing|
|Pacritinib||See Pricing||Oxygen linked pyrimidine derivatives||Cell Therapeutics, Inc. (Seattle, WA)||See Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|